跳至主要内容
临床试验/IRCT2016030917006N2
IRCT2016030917006N2已完成未知

Evaluation of the protective effects of nanocurcumin against iodine therapy's side effects in thyroid cancer patients: a randomized, double-blind, placebo-controlled clinical trial

Vice chancellor for research, Mashhad University of Medical Sciences. (Primary sponsor)0 个研究点目标入组 90 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
All

入选标准

  • age between 18 to 65; patients with papillary or follicular thyroid cancer; Desire to join to study
  • Exclusion criteria: previous history of radioiodine therapy; history of head and neck radiotherapy; previous history of thyroid surgery; pregnancy; lactation; history of chronic rheumatologic disease; history of LASIK or PRK on eye or surgery of salivary glands; PT less than normal

排除标准

  • 未提供

研究者

发起方
Vice chancellor for research, Mashhad University of Medical Sciences. (Primary sponsor)

相似试验

The protective effects of nanocurcumin against... | 临床试验